Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Introduction Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to...

Full description

Saved in:
Bibliographic Details
Main Authors: Toby M Maher, Michael Kreuter, Vincent Cottin, Daniel Wachtlin, Anna-Maria Hoffmann-Vold, Marlies S Wijsenbeek, Fernando J Martinez, Shervin Assassi, Luca Richeldi, Arata Azuma, Justin M Oldham, Claudia Valenzuela, Carl Coeck, Christina Schlecker, Florian Voss
Format: Article
Language:English
Published: BMJ Publishing Group 2023-07-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/10/1/e001580.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopenrespres.bmj.com/content/10/1/e001580.full

Similar Items